苯乙双胍抑制髓源性抑制细胞并增强黑色素瘤PD-1阻断抗肿瘤活性
该研究在小鼠黑色素瘤模型中探讨双胍类药物苯乙双胍对肿瘤微环境的影响。苯乙双胍选择性抑制荷瘤小鼠脾脏及体外的粒细胞性髓源性抑制细胞,并依赖活性氧产生;与抗PD-1抗体联用可增强抑制肿瘤生长、促进CD8+ T细胞浸润并降低髓源性抑制细胞免疫抑制相关蛋白水平。
要点
- 苯乙双胍选择性抑制粒细胞性髓源性抑制细胞。
- 其抑制作用与活性氧产生相关,N-乙酰半胱氨酸可减弱该效应。
- 苯乙双胍联合抗PD-1增强黑色素瘤小鼠抗肿瘤免疫。
核心结论
- 苯乙双胍对粒细胞性髓源性抑制细胞驱动的免疫抑制具有选择性抑制作用。
- 苯乙双胍可改善PD-1阻断免疫治疗在黑色素瘤中的抗肿瘤活性。
研究设计与样本
- 研究在荷瘤小鼠脾脏及体外实验中观察苯乙双胍对髓源性抑制细胞的影响。
- 使用BRAF V600E/PTEN缺失黑色素瘤小鼠模型评估苯乙双胍与抗PD-1抗体联合治疗。
主要发现
- 苯乙双胍选择性抑制荷瘤小鼠脾脏及体外的粒细胞性髓源性抑制细胞。
- 苯乙双胍诱导粒细胞性髓源性抑制细胞产生活性氧,抗氧化剂N-乙酰半胱氨酸减弱其抑制作用。
- 苯乙双胍与抗PD-1联合协同诱导CD8+ T细胞浸润并降低髓源性抑制细胞免疫抑制关键蛋白水平。
临床怎么用
- 提示苯乙双胍可能作为增强黑色素瘤PD-1阻断疗效的联合策略。
局限性
- 结论主要基于小鼠模型和体外实验,尚未在人体中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biguanides, such as the diabetes therapeutics metformin and phenformin, have shown antitumor activity both in vitro and in vivo. However, their potential effects on the tumor microenvironment are largely unknown. Here we report that phenformin selectively inhibits granulocytic myeloid-derived suppressor cells in spleens of tumor-bearing mice and ex vivo. Phenformin induces production of reactive oxygen species in granulocytic myeloid-derived suppressor cells, whereas the antioxidant N-acetylcysteine attenuates the inhibitory effects of phenformin. Co-treatment of phenformin enhances the effect of anti-PD-1 antibody therapy on inhibiting tumor growth in the BRAF V600E/PTEN-null melanoma mouse model. Combination of phenformin and anti PD-1 cooperatively induces CD8+ T-cell infiltration and decreases levels of proteins that are critical for immune suppressive activities of myeloid-derived suppressor cells. Our findings show a selective, inhibitory effect of phenformin on granulocytic myeloid-derived suppressor cell-driven immune suppression and support that phenformin improves the anti-tumor activity of PD-1 blockade immunotherapy in melanoma.
引用
- Kim SH, Li M, Trousil S, et al. Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma. J Invest Dermatol. 2017. PMID: 28433543. doi:10.1016/j.jid.2017.03.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。